-
公开(公告)号：US11524046B2
公开(公告)日：2022-12-13
申请号：US16391272
申请日：2019-04-22
Applicant: ContraFect Corporation
Inventor： Raymond Schuch , Robert C. Nowinski , Michael Wittekind , Babar Khan , Jimmy Rotolo
Abstract: The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.
-
公开(公告)号：US11413334B2
公开(公告)日：2022-08-16
申请号：US16924681
申请日：2020-07-09
Applicant: CONTRAFECT CORPORATION
Inventor： Raymond Schuch , Simon Hoffenberg , Michael Wittekind
IPC: A61K38/47 , A61K38/12 , A61K45/06 , A61K9/00 , A61K31/7036 , A61K38/46 , A61K38/16 , A61P31/04 , C12N9/36
Abstract: The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa. The disclosure further provides compositions and methods of incorporating and utilizing lysin polypeptides of the present disclosure for augmenting the efficacy of antibiotics generally suitable for the treatment of Gram-negative bacterial infection.
-
3.发明申请COMPOSITION AND METHODS BASED ON NEUTRALIZING ANTIBODIES DELIVERED INTRANASALLY FOR ENHANCED THERAPEUTIC EFFICACY 审中-公开基于中性递送抗体的组合物和方法用于增强治疗效果公开(公告)号：US20170002062A1
公开(公告)日：2017-01-05
申请号：US15268091
申请日：2016-09-16
Applicant: ContraFect Corporation
Inventor： Michael Wittekind , Adam Vigil
CPC classification number: C07K16/1018 , A61K9/0043 , A61K9/007 , A61K39/42 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/543 , A61K2039/544 , A61K2039/545 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/76
Abstract: The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration. The invention provides compositions suitable for intranasal or inhalation treatment and administration. The invention includes methods for treatment or prophylaxis combining intranasal or inhalation administration with intraperitoneal or intravenous administration of antibodies.
Abstract translation: 本发明通过直接向呼吸道施用药剂，特别是中和抗体或其活性片段，包括通过鼻内或吸入给药，提供了治疗或预防病毒，特别是流感病毒的方法。 本发明提供适用于鼻内或吸入治疗和给药的组合物。 本发明包括治疗或预防鼻内或吸入给药与腹膜内或静脉内施用抗体的方法。
-
4.发明申请公开(公告)号：US20150111813A1
公开(公告)日：2015-04-23
申请号：US14399588
申请日：2013-05-09
Applicant: CONTRAFECT CORPORATION
Inventor： Raymond Schuch , Robert C. Nowinski , Michael Wittekind , Babar Khan , Jimmy Rotolo
IPC: C07K14/315 , A61L29/08 , A01N63/00 , A61L29/16 , A61K38/16
CPC classification number: A01N63/00 , A61K38/16 , A61K38/164 , A61K38/47 , A61K45/06 , A61L29/08 , A61L29/16 , A61L2300/404 , A61L2300/406 , A61L2420/00 , C07K14/315 , C12N9/503 , C12Y302/01017
Abstract: The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.
Abstract translation: 本发明提供了用赖素，特别是具有杀死葡萄球菌细菌（包括耐药性金黄色葡萄球菌，特别是赖氨酸PlySs2）的能力的赖氨酸来预防，控制，破坏和治疗细菌生物膜的方法。 本发明还提供了用于治疗或调节细菌生物膜和生物膜形成的组合物和方法。
-
公开(公告)号：US20220111049A1
公开(公告)日：2022-04-14
申请号：US17560830
申请日：2021-12-23
Applicant: CONTRAFECT CORPORATION , TRELLIS BIOSCIENCE, LLC
Inventor： Angeles Estelles , Lawrence M. Kauvar , Adam Vigil , Michael Wittekind
Abstract: Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that bind near the HA0 maturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.
-
Patent Agency Ranking
6.发明申请BACTERIOPHAGE LYSIN AND ANTIBIOTIC COMBINATIONS AGAINST GRAM POSITIVE BACTERIA 审中-公开BACTERIOPHAGE LYSIN和抗生素组合对抗真菌细菌公开(公告)号：US20150290299A1
公开(公告)日：2015-10-15
申请号：US14399575
申请日：2013-05-09
Applicant: CONTRAFECT CORPORATION
Inventor： Raymond Schuch , Robert C. Nowinski , Michael Wittekind , Han Lee , Brent Schneider
IPC: A61K38/47 , A61K45/06 , A61K31/5377 , A61K38/12 , A61K31/4188
Abstract: The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).
Abstract translation: 本发明提供用于预防，改善和治疗革兰氏阳性细菌，特别是葡萄球菌的组合物和溶解素，特别是链球菌赖氨酸，特别是赖氨酸PlySs2和一种或多种抗生素，包括达托霉素，万古霉素，苯唑西林，利奈唑胺 ，或相关的抗生素。
-
公开(公告)号：US11246928B2
公开(公告)日：2022-02-15
申请号：US16674149
申请日：2019-11-05
Applicant: CONTRAFECT CORPORATION , TRELLIS BIOSCIENCE, LLC
Inventor： Angeles Estelles , Lawrence M. Kauvar , Adam Vigil , Michael Wittekind
Abstract: Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that hind near the HA0 maturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.
-
公开(公告)号：US10813983B2
公开(公告)日：2020-10-27
申请号：US14399575
申请日：2013-05-09
Applicant: CONTRAFECT CORPORATION
Inventor： Raymond Schuch , Robert C. Nowinski , Michael Wittekind , Han Lee , Brent Schneider
IPC: A61K38/46 , C12N9/50 , A61K31/4188 , A61K31/5377 , A61K38/12 , A61K38/47 , A61K45/06 , A61K38/14
Abstract: The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).
-
公开(公告)号：US10744189B2
公开(公告)日：2020-08-18
申请号：US15760283
申请日：2016-09-16
Applicant: ContraFect Corporation
Inventor： Raymond Schuch , Simon Hoffenberg , Michael Wittekind
IPC: A61K38/47 , A61K38/12 , A61K45/06 , A61K9/00 , A61K31/7036 , A61K38/46 , A61K38/16 , A61P31/04 , C12N9/36
Abstract: The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa. The disclosure further provides compositions and methods of incorporating and utilizing lysin polypeptides of the present disclosure for augmenting the efficacy of antibiotics generally suitable for the treatment of Gram-negative bacterial infection.
-
公开(公告)号：US11827693B2
公开(公告)日：2023-11-28
申请号：US14769795
申请日：2014-03-14
Applicant: CONTRAFECT CORPORATION
Inventor： Michael Wittekind , Adam Vigil
CPC classification number: C07K16/1018 , A61K9/007 , A61K9/0043 , A61K39/42 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/543 , A61K2039/544 , A61K2039/545 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/76
Abstract: The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration. The invention provides compositions suitable for intranasal or inhalation treatment and administration. The invention includes methods for treatment or prophylaxis combining intranasal or inhalation administration with intraperitoneal or intravenous administration of antibodies.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.016 seconds)
